Compare DH & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DH | CADL |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.1M | 1.0B |
| IPO Year | 2021 | 2021 |
| Metric | DH | CADL |
|---|---|---|
| Price | $0.99 | $10.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $3.08 | ★ $19.00 |
| AVG Volume (30 Days) | 811.7K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.28 | 58.62 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $241,521,000.00 | $125,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.74 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.61 | $4.35 |
| 52 Week High | $4.35 | $14.00 |
| Indicator | DH | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 59.06 | 41.77 |
| Support Level | $0.93 | $9.40 |
| Resistance Level | $1.24 | $11.36 |
| Average True Range (ATR) | 0.07 | 0.69 |
| MACD | -0.01 | -0.28 |
| Stochastic Oscillator | 42.51 | 27.99 |
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.